Stock Events

Stock Events

Protokinetix 

$0.000200
6
+$0.00+0% Friday 20:00

Statistics

Day High
0.0063
Day Low
0.0063
52W High
0.0124
52W Low
0.0001
Volume
2,962
Avg. Volume
51,725
Mkt Cap
78,316
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

31OctExpected
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-0
-0
-0
-0
Expected EPS
N/A
Actual EPS
-0.0013

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-364,000Net Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. competes in the biotechnology field focusing on developing treatments for eye diseases, inflammatory conditions, and cancer, similar to Protokinetix's focus on therapeutic applications.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals Incorporated is involved in creating therapies for treating cystic fibrosis and other serious diseases, competing in the biotech sector with innovative treatments.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that develops and markets medicines in areas of unmet medical need, overlapping with Protokinetix's mission.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. is a biotechnology pioneer that discovers, develops, manufactures, and delivers innovative human therapeutics, similar to Protokinetix's work in biotech.
Biogen
BIIB
Mkt Cap32.28B
Biogen Inc. focuses on developing therapies for neurological diseases, competing with Protokinetix in the broader biotech and therapeutic research industry.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics AG is a gene editing company that develops transformative gene-based medicines for serious diseases, presenting a competitive edge in innovative treatments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals, Inc. is engaged in the discovery, development, and commercialization of RNA interference (RNAi) therapeutics, a novel approach that could compete with Protokinetix's therapeutic strategies.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk A/S is a global healthcare company with more than 95 years of innovation and leadership in diabetes care, also expanding into biopharmaceuticals, potentially competing with Protokinetix.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical Inc. specializes in enzyme replacement therapies and other novel treatments for rare genetic diseases, competing in the innovative treatment space similar to Protokinetix.

About

ProtoKinetix, Incorporated is a biotechnology firm engaged in research and development, specializing in the scientific and medical investigation of glycoproteins known as anti-freeze glycoproteins (AFGPs) and anti-aging glycoproteins (AAGPs). These AFGPs are particularly relevant for their commercial potential within the healthcare sector, with a key area of their development involving utilizing AAGPs for the treatment of dry-eye conditions. Their research efforts are bolstered by a collaborative agreement with the University of British Columbia. Originally incorporated in 1999 as RJV Network, Inc., the company adopted its current name, ProtoKinetix, Incorporated, in July 2003. Its operational headquarters are situated in Marietta, Ohio.
Show more...
CEO
Michael Richard Guzzetta
Employees
5
Country
United States
ISIN
US7437221002

Listings

OTC Link
US
PKTX

0 Comments

Share your thoughts

FAQ

What is Protokinetix stock price today?▼
The current price of PKTX is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Protokinetix stock price performance more closely on the chart.
What is Protokinetix stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Protokinetix stocks are traded under the ticker PKTX.
Is Protokinetix stock price growing?▼
PKTX stock has fallen by -0% compared to the previous week, the month change is a -50% fall, over the last year Protokinetix has showed a -96.36% decrease.
What is Protokinetix market cap?▼
Today Protokinetix has the market capitalization of 78,316
What were Protokinetix earnings last quarter?▼
PKTX earnings for the last quarter are -0 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Protokinetix revenue for the last year?▼
Protokinetix revenue for the last year amounts to 0 USD.
What is Protokinetix net income for the last year?▼
PKTX net income for the last year is -364,000 USD.
How many employees does Protokinetix have?▼
As of September 05, 2026, the company has 5 employees.
In which sector is Protokinetix located?▼
Protokinetix operates in the Health & Wellness sector.
When did Protokinetix complete a stock split?▼
Protokinetix has not had any recent stock splits.
Where is Protokinetix headquartered?▼
Protokinetix is headquartered in Dalton, United States.